Company Introduction
Digital Therapeutics Powered by AI and VR
Hippo T&C is a digital healthcare company developing evidence-based solutions for mental health and child neurodevelopment using VR and AI. Its flagship product, BlueKare, is an eight-week CBT-based mobile program for major depressive disorder and Korea’s first MFDS-approved digital therapeutic for depression. It is also designated as an innovative medical device. The portfolio includes WithBuddy for everyday mind care, CogMo for VR/AI-based child behavioral assessment and training, and MHA+ for AI mental health assessment. AttnKare-D, which supports ADHD diagnosis, is in a confirmatory clinical trial, while EunoKare for bipolar disorder is preparing for one. With scientific rigor, patient-centered design, privacy, and safety at its core, Hippo T&C delivers accessible solutions for hospitals, schools, companies, and public institutions.
